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Background: Significant emphasis is currently placed on the need to enhance health care decision-making with
research-derived evidence. While much has been written on specific strategies to enable these “knowledge-to-action”
processes, there is less empirical evidence regarding what happens when knowledge translation (KT) processes do not
proceed as planned. The present paper provides a KT case study using the area of health care screening for intimate
partner violence (IPV).
Methods: A modified citation analysis method was used, beginning with a comprehensive search (August 2009 to
October 2012) to capture scholarly and grey literature, and news reports citing a specific randomized controlled trial
published in a major medical journal on the effectiveness of screening women, in health care settings, for exposure to
IPV. Results of the searches were extracted, coded and analysed using a multi-step mixed qualitative and quantitative
content analysis process.
Results: The trial was cited in 147 citations from 112 different sources in journal articles, commentaries, books, and
government and news reports. The trial also formed part of the evidence base for several national-level practice
guidelines and policy statements. The most common interpretations of the trial were “no benefit of screening”, “no
harms of screening”, or both. Variation existed in how these findings were represented, ranging from summaries of the
findings, to privileging one outcome over others, and to critical qualifications, especially with regard to methodological
rigour of the trial. Of note, interpretations were not always internally consistent, with the same evidence used in
sometimes contradictory ways within the same source.
Conclusions: Our findings provide empirical data on the malleability of “evidence” in knowledge translation processes,
and its potential for multiple, often unanticipated, uses. They have implications for understanding how research
evidence is used and interpreted in policy and practice, particularly in contested knowledge areas.
Keywords: Citation analysis, Domestic violence, Knowledge translation, Practice guidelines, Research utilizationBackground
It has been over 20 years since intimate partner violence
(IPV) was declared to be a major public health problem
[1], and while data on the prevalence [2-5], conse-
quences [6-10], and costs [11-14] are well-established,
many gaps remain in the knowledge base regarding how* Correspondence: nwathen@uwo.ca
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reproduction in any medium, provided the orthe health care sector can best detect and respond to
IPV. These gaps have led to debates in the field and
conflicting advice to health and social service providers,
and policy decision-makers [15,16].
One of the most contested areas is whether or not all
women should be routinely screened by a health care
provider for exposure to IPV. Proponents argue that
IPV’s burden of suffering necessitates universal screening
of all women presenting to healthcare settings [17,18]
with the hope that this will lead women on a path ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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its health consequences. A number of evidence-based re-
views and guidelines have concluded that the lack of evi-
dence regarding the benefits, and potential harms and
costs, of such screening on women’s health and well-
being favours a case-finding approach (assessment of a
patient based on risks for, and/or clinical signs or symp-
toms of, exposure) [19-21]. A recent updated systematic
review for the US Preventive Services Task Force con-
cluded that, while there may not be evidence from
screening trials indicating benefit to women, the fact
that screening can identify women, and that some inter-
vention studies show promise for some women, warrants
inclusion of universal screening protocols in health care
settings [22].
This situation is typical of many health topics, where
there is imperfect yet evolving research evidence, and a
variety of interested and invested stakeholders who de-
velop, promote and/or enact specific policies or prac-
tices, and who may or may not wish these options to be
informed by “evidence” [23]. What makes this case inter-
esting for empirical analysis is the increased policy activ-
ity in the field in 2011–12, especially in, but not limited
to, the USA.
The “case” – a randomized controlled trial of IPV
screening
In 2009, in the Journal of the American Medical Asso-
ciation (JAMA), the results of a multi-site Canadian
randomized controlled trial (RCT) were published indi-
cating that universal screening for IPV did not signifi-
cantly reduce women’s exposure to violence, or improve
health outcomes or quality of life [24] (hereafter referred
to as ‘the IPV screening trial’ or ‘the trial’). This was ac-
companied by an editorial recommending that until
screening is shown to have measurable benefits for
abused women, a case-finding approach, as defined
above, is the best clinical response [25]. The key mes-
sages arising from the trial are outlined below. During
the course of the current analysis, a second large RCT,
conducted in the USA and also addressing IPV screening
in health care settings, was published in JAMA, with
very similar findings [26]; it too had an accompanying
editorial re-emphasizing the need for clinical case-
finding [27].
Given the debate surrounding this issue, we sought to
examine how the evidence from the initial trial, pub-
lished in a widely-read medical journal, has become rep-
resented in the literature, and to what extent it has
influenced practice guidelines and policies. The trial –
the largest of its kind at the time providing direct evi-
dence regarding the effectiveness of screening in health
care settings – also came at a significant moment in the
evolution of the debate regarding the health care res-ponse to IPV, especially in the USA, where, as we will
describe, recent clinical and legislative bodies have taken
a position on this issue.
Summary of key messages arising from the IPV screening
trial
Key findings:
 All women in the trial showed reductions in
exposure to violence across time – these were not
associated with screening.
 Small differences between groups on life quality and
depression were not statistically significant when the
analysis accounted for women lost to follow-up, nor
were they clinically meaningful. There were no
differences in women’s health outcomes.
 Screened and control group women had no
differences in the frequency of using violence-related
health and social services.
 Screening may over-identify women as experiencing
IPV, and many women must be screened to identify
one woman who discloses abuse.
 There were no short-term direct harms of screening
as implemented in this RCT.
 Sample attrition was a concern, and data analysis
that accounted for these losses to follow-up further
reduced differences between groups.
Trial conclusions:
 Health care providers and settings should be alert to
the signs and symptoms associated with IPV exposure
and ask questions about abuse when these are present
(clinical case finding), ensuring that women are asked
in sensitive ways to help identify their needs and safety
concerns. Further, health care settings should develop
and implement protocols for referral of abused
women, according to their needs, to local services.
Framing the case study: knowledge translation
Significant emphasis is currently placed on the need to en-
hance health decision-making processes with the best
research-derived evidence available regarding specific
health care practices and/or policies [28]. Indeed, most re-
search funding agencies now require explicit “knowledge
translation” (KT) (or “dissemination and implementation”)
plans, including how “knowledge users” might be involved
in research, from inception to communication. Numerous
potential strategies exist to bridge the “know-do” gap and
this area has grown into its own field of study [29-32]. How-
ever, a number of authors have started to question some
of the assumptions that underlie the rationale of KT, includ-
ing basic concepts, such as the nature of the “evidence”
or knowledge that is supposed to be “translated” [33],
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influencing behaviours and decisions [34,35].
Thus, while much has been written on specific strat-
egies to enable “knowledge-to-action” processes, there is
less empirical evidence regarding what happens when
these processes do not follow the proscribed logic, or
yield unanticipated outcomes. One concept we explore
is whether evidence can be thought of as “malleable”,
that is, open to shaping and changing in ways that may
or may not fit with its initial presentation. The present
paper provides an empirical KT case study using the area
of health care screening for IPV. Our specific research
questions were: 1) how have authors and organizations
interpreted and used the trial report? and, 2) how has it
influenced practice guidelines and policies?
Methods
No single validated method exists for conducting the kind
of citation identification and analysis process we deemed
necessary for understanding the broad representation and
use of the IPV screening trial results; assessing research
use in various contexts is a notoriously difficult task
[36,37]. Therefore, we created a comprehensive search and
analysis strategy, which we call a ‘modified citation ana-
lysis’, to capture both scholarly and grey literature, includ-
ing news reports, using aspects of the method described
by Jones et al. [36]. Traditional citation analysis is a widely
used bibliometric tool used to examine links, within the
scholarly literature, among published works [38]. While
there are flaws to this method of analysis (e.g., undervalu-
ing recent papers) [39,40], it has been the basis for plat-
forms such as Web of Science and Google Scholar.
Our modified approach included three main steps to col-
lect citations from: 1) scholarly/academic peer-reviewed
sources; 2) grey literature, defined as “that which is pro-
duced on all levels of governmental, academic, business
and industry in print and electronic formats, but which is
not controlled by commercial publishers” [41], p. 2, which
is often difficult to find through conventional search tools;
and 3) news reports. Keywords varied depending on the
tool, website, or database used and included: “MacMillan”,
“JAMA” and/or “Journal of the American Medical Associ-
ation”, “violence”, “screening”, “2009”. The only inclusion
criterion was that the source needed to cite the IPV screen-
ing trial. Dissertations, although considered grey literature,
were excluded, as they were, in themselves, unlikely to be
influential in terms of practice or policy considerations, es-
pecially in the context of the data set, which was almost
exclusively composed of studies conducted in high-income
countries. Conference proceedings were also excluded due
to the difficulty of searching and obtaining presentation
documents that may have included the relevant citation.
Although we included books that came up in our searches
and searched several full-text online book databases (e.g.,Google Books) we did not search for this particular source
format exhaustively as no single database allows a compre-
hensive search of the references of all published books.
Searches included works published between August
2009 (when the trial was published) and October 2012. In
Step 1, we began searching the scholarly literature by
using Web of Science [42], a widely recognised citation
searching tool accessing thousands of journals across mul-
tiple scholarly disciplines, including those relevant to this
topic. We also used JAMA’s ‘cited by’ tool which allowed
us to easily search for JAMA and related American Me-
dical Association (AMA) Archives journal articles citing
the trial, as well as Google Scholar (which has a ‘cited
by’ tool), Google Scholar updates (which automatically
emailed us relevant journal articles or books), and Scopus.
In Step 2, we searched the grey literature using a targeted
search of a variety of inter- and cross-disciplinary database
search engines that feature both academic and grey litera-
ture (including MedLine Plus, MDConsult, UpToDate,
etc.). A general Google search was also conducted (not
reported) to ensure nothing was missed (see Additional
file 1 for a complete list of databases searched and search
results, including all cited sources). We also ‘hand searched’
the websites of those major healthcare professional associa-
tions (e.g., AMA) and organizations (e.g., American
Academy of Family Physicians) that were likely to in-
clude IPV-related content. In Step 3, we searched news
reports, using key news databases including Factiva,
Lexis Nexis, Google News, and Proquest Canadian
Major Dailies (see Figure 1 for search flow diagram).
All relevant sources were stored in the online refer-
ence management program RefWorks. Coding was
conducted in three phases, to meet separate, but related,
goals of developing a broad understanding of how the
IPV screening trial was represented both explicitly and
implicitly, and to interpret this in the broader context of
the IPV evidence base and emerging practice and policy
guidance. In Phase I, we wanted to explore how the IPV
screening trial was used explicitly in each source. To do
this we copied, verbatim, into a spreadsheet the text
from each source (ranging from phrases to multiple par-
agraphs) that explicitly cited the trial; where a source
cited the trial more than once, each section of text was
extracted separately for analysis (that is, one source
could have multiple extractions). Phase I analysis of the
text took place in three steps. First, using content ana-
lysis [43], two team members (SS and JM; neither of
whom were associated with the original IPV screening
trial) independently coded all extractions to create a
coding scheme. The coding scheme was created induct-
ively, and guided by the extractions. Once the coding
scheme was created, all extractions were re-coded (by
JM and SS). The coding scheme had nine thematic codes
(such as harm/benefit and methodology), with 26 sub-
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Used article title as 
search term
Used a variety of 
search terms and 
combinations
Used journal title, 
author name & 
article title (alone, 
& in combination)
Total 186 Records Total 184 Records Total 9 Records
Step 2: Total 114 unique or true hits 
(duplicates and MacMillan/Wathen self-citations removed)
Step 3: Total 114 records 




Step 4: Total 112 records included in analysis
Scholarly Literature = 97
(64 research articles 
including lit. reviews, 12 
books, 16 commentaries, 3 
practice guidelines, 2 
other)
Grey Literature = 15
(5 reports, 1 practice guideline, 9 newspaper 
reports)
*Google Scholar and Google Scholar Update also index books
**one was a dissertation and the other did not actually cite the trial
Figure 1 Search results flow diagram.
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Each extraction was coded to reflect how the trial was be-
ing used (for example to support screening or to provide
evidence for no harm of screening). Any extraction that
cited the trial’s major finding of ‘no benefit’, and/or of ‘no
harm’, was also coded to include further explanation
(if any) regarding the implications of this finding. All co-
ding was consolidated between the two coders; disagree-
ments between coders were resolved through re-review
and discussion of the extracts. Potential quotes/extrac-
tions that could be used in the qualitative analysis to em-
phasise these themes were pre-selected (by JM and SS)
from the data set without involvement of NW or HM.
Final decisions on which of these was included in the
manuscript were made by the lead author (NW).
In Phase II, we looked at the source itself (i.e., where the
extraction came from) and coded each source in two
steps. First, each source (based on the title, abstract, or
full-text when no abstract was available) was coded as ei-
ther mainly focused on IPV screening or not. Next, rele-
vant text (i.e., on the topic of IPV screening, often from
the Conclusions or Summary) was extracted from each
source. Using a directed coding approach, each source
was categorized into one of four categories: supports
screening, does not support screening, unclear, or no pos-
ition. Where appropriate, sources were then further in-
ductively coded into explicit support or non-support,
implicit support or non-support. To do this, the content,
including the research question and/or use of language,
was examined and interpreted by the two coders to either
imply support or not, or other more specific categories
(such as: implied based on use in one specific targetpopulation). In the case of coding disagreements (which
were rare), both coders went back to the original source
or extraction to re-code material that caused the disagree-
ment, and a final code was decided by consensus.
Finally, in Phase III, and consistent with the variability
in how “screening” is defined and discussed, we examined
how each source used the term “screening”, and induct-
ively coded whether or not the term was explicitly defined.
Only sources that had an explicit definition of screening
were further coded (e.g., screening defined as healthcare
professional routinely asking all women about abuse).
For all three phases of coded results, descriptive statis-
tics (frequencies) were generated using SPSS 20.0. De-
tails of the coding process, the search results, and the
full bibliographic details of all sources citing the IPV
screening trial are found in Additional file 1.
Results
We present the results in two ways. First, data are quan-
titatively summarized in Tables 1 and 2 to address the
research question regarding the number and types of
sources that cite the trial, and specific ways that this was
done in the context of those sources. Next, themes are
presented that emerged from the analysis regarding how
the IPV screening trial was represented; we used
extracted text from the sources to exemplify and begin
to interpret these themes more qualitatively.
How the IPV screening trial was cited, and in what
context
In total, we found 147 instances of the trial being cited
(“extractions”) in 112 different sources, as summarized in
Table 1 Summary of characteristics of citing sources
Source type n (% of 112 sources)
Research article 56 (50%)
Commentary 16 (14.3%)
Books or book chapters 12 (10.7%)
News reports 9 (8%)
Practice guidelines 4 (3.6%)
Grey literature (e.g., government) reports 5 (4.5%)
Literature review (non-systematic) 4 (3.6%)
Literature review (systematic) 4 (3.6%)
Other 2 (1.8%)
Source content regarding IPV
screening
n (%) (of 112)
IPV Screening focus (yes) 55 (49.1%)
Define screening (yes) 13 (11.6%)
Support universal screening 35 (31.3%)
Do not support universal screening 28 (25%)
Unable to determine/no position on
screening
49 (43.8%)
Times citing trial (within source)
(range 1–5)
n (%) (of 112)
Once 90 (80.4%)
2-3 times 21 (18.8%)
5 times 1 (0.9%)






Unable to specify (non-sectioned source) 55 (37.4%)
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understand the context within which each citation was
placed, we examined several aspects of each source with
respect to its IPV-related content and its position on
screening more specifically (Table 1). Almost half of the
sources were focused on the issue of IPV screening (49%).
Only 13 sources (12%) explicitly defined screening, 8 (15%)
among those that focused on IPV screening, and 5 (9%)
among those that did not. The definitions took many
forms. For example, whereas some definitions included
screening plus a follow-up intervention (e.g., referral, brief
counselling) as integral to the clinical screening process
(n = 3, 23%), most did not (n = 10, 77%). Some, but not all,
specified who should be asked (n = 6, 46%), for example,
“women and adolescents” [44], p. 166, “asymptomatic per-
sons,” [45], p. 725, or “all women or patients regardless of
presumed risk” [48], p. 856. We also examined the position
that each source took on IPV screening; 35 sources (31%)
supported it, with support explicitly stated in 21 instances,
six of which added a caveat to their support (e.g., privacy ofwomen must be ensured during a screening encounter). In
the remaining 14 (13%) instances, support for IPV screen-
ing was implied through language or by the research
methods, for example, when authors included the imple-
mentation of IPV screening as a positive outcome variable
in their research [46]. Many sources were coded as not
supporting universal IPV screening (25%), again, some ex-
plicitly so (4%), and others implying their position (21%),
for example by explicitly supporting screening in a specific
population only (e.g., in reproductive or sexual health set-
tings). In 10 instances (9%), coders were unable to deter-
mine the authors’ position (if any), and the remaining 39
(35%) were seen as taking no position, either because they
did not address the issue of IPV screening, or because they
presented no stance regarding screening.
Table 2 describes how these 147 individual extractions
cited the trial. Over half (55%) of the sources cited the
trial’s major findings of ‘no benefit of screening’, ‘no
harm of screening’, or both, in at least one extraction
(n = 35, 14, and 20 extractions, respectively). The trial
was also cited for a variety of other reasons such as to
support provider education or justify a statistical or
methodological approach. A fairly common approach
was to use the trial as a more general IPV or screening
reference (35%). For example, some cited the trial for
the general conclusion that there is insufficient evidence
to recommend universal screening (16%) or for the fact
that a debate regarding IPV screening exists (11%).
Other extractions focused on secondary findings repor-
ted in the trial (21%), such as the number of women in
the RCT who did or did not have an IPV discussion with
their healthcare provider (9%) or the RCT’s retention
rate (5%). In 10% of cases, the trial was cited to support
the statement that there is a research priority or know-
ledge gap in the area of interventions/services for IPV.
Of the 14 citations referring to the trial’s finding of ‘no
harms of screening,’ one further elaborated, stating the im-
portance of considering whether ‘safety concerns’ as con-
ceptualized by MacMillan et al. “adequately captures the
possible harm associated with screening for IPV” [47],
p. 7. The ‘no benefit of screening’ finding was further ela-
borated in 34% of instances (n = 12 of 35 citations).
Authors commented on this finding by identifying meth-
odological and/or statistical limitations in the trial; the fol-
lowing were all single instances of these comments, unless
otherwise indicated: 1) that no designated intervention oc-
curred after screening; 2) that the control group was also
administered questions about IPV (i.e., after the clinical
visit; n = 2); 3) that the experiences (e.g., of abuse or ser-
vice access) of the women in the sample were too varied
to find beneficial effects of screening; 4) poor screening
method used; 5) the lack of designated intervention com-
bined with the fact that most women accessed services
prior to screening; 6) the lack of designated intervention
Table 2 How the IPV screening trial was cited (147 extractions from 112 sources)
Code/Sub-code # sources given code
(at least once) (% of 112)
# times code used for
extraction (% of 147)
1. Major finding (Harm/Benefit): Used when IPV screening trial major finding cited: 61 (54.5) 80 (54.4)
1.1 No harm from screening 13 (11.6) 14 (9.5)
1.2 No benefit to screening 33 (29.5) 35 (23.8)
1.3 Both (no harm/no benefit) 20 (17.9) 20 (13.6)
1.4 Benefit to screening 8 (7.1) 8 (5.4)
1.5 Results inconclusive 2 (1.8) 2 (1.4)
2. Methods/Measures/Statistics: Used when IPV screening trial method or measure
cited:
19 (17) 21 (14.3)
2.1 Women-centred outcomes 2 (1.8) 3 (2)
2.2 Multi-level modelling 1 (.9) 1 (.7)
2.3 Harms 3 (2.7) 3 (2)
2.4 CAS cut-off 2 (1.8) 2 (1.4)
2.5 WAST 2 (1.8) 3 (2)
2.6 Other methods/measures/statistics 9 (8) 9 (6.1)
3. General screening/IPV reference: Used to cite IPV screening trial for general point
about screening or IPV:
43 (38.4) 51 (34.7)
3.1 Screening debate 15 (13.4) 16 (10.9)
3.2 Importance of IPV/screening discussion 2 (1.8) 2 (1.4)
3.3 HCP education/training 2 (1.8) 2 (1.4)
3.4 Other 6 (5.4) 7 (4.8)
3.5 Insufficient evidence to support screening 23 (20.5) 24 (16.3)
4. Interventions/Services: Used when IPV screening trial cited to show priority and/or
research/knowledge gap in the area of interventions/services for IPV
13 (11.6) 14 (9.5)
5. Minor findings: Used when a minor IPV screening trial finding cited: 22 (19.6) 31(21.1)
5.1 Effect size 1 (.9) 1 (.7)
5.2 Retention rate 8 (7.1) 8 (5.4)
5.3 Women not talking to HCP 8 (7.1) 8 (5.4)
5.3a Women talking to HCP 4 (3.6) 5 (3.4)
5.4 Sensitivity 2 (1.8) 2 (1.4)
5.5 Other minor finding 7 (6.3) 7 (4.8)
6. No specific citation: Used when IPV screening trial listed as a reference or a source for
readers to consult (but nothing specific cited in text)
3 (2.7) 3 (2)
7. Incorrect: Used when IPV screening trial cited incorrectly (e.g., for a finding not actually
reported)
2 (1.8) 3 (2)
8. Other: Used when no other code appropriate, especially when reason for citing IPV
screening trial is unclear
2 (1.8) 2 (1.4)
Note: Each extraction received a maximum of three distinct codes. Some sources were given more than one sub-code per category. IPV: Intimate partner violence;
HCP: Health care provider; CAS: Composite Abuse Scale [48]; WAST: Woman Abuse Screening Tool [49].
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assessed, as part of the research process, on IPV exposure;
or 7) attrition, sometimes combined with a comment
about one of the following: statistical analysis methods,
lack of a designated intervention, control group admi-
nistered IPV questions or controlled conditions along with
unspecified methodological problems.
Among the 20 citations referring to both ‘benefit’ and
‘harm’ findings, six were qualified by the authors. However,
in four citations the qualification was specific to the ‘nobenefit’ finding, not the ‘no harm’ finding (i.e., highlighting
the fact that no intervention was provided after screening,
that the control group was exposed to the intervention
(n = 2), or both). Of these four sources, three explicitly
supported universal IPV screening and one supported
screening in a specific population.
A key theme evident across most sources, especially those
with an implicit or explicit pro-screening position, was to
contest or offer an alternative explanation for the trial’s
main finding of ‘no benefit’. As indicated above, this was
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sometimes through re-iteration of those articulated in the
JAMA report [44,50], and other times through extrapola-
tions of these limitations, as indicated in the following:
“. . . recent randomized trials suggest that screening
does not reduce reabuse or lead to significant
differences on other quality of life or safety outcomes
(Koziol-McLain et al., 2010; MacMillan et al., 2009).
On face-value such findings would suggest that there
is little merit in screening; however high loss to follow
up (MacMillan et al., 2009), and insufficient sample
size for effect (Koziol-McLain et al., 2010) limit the
robustness of these findings.” [51], p. 151.
And,
“. . . methodological issues (i.e., sample attrition and
exposure to the intervention in the control group)
[emphasis added] of a recent randomized, controlled
trial rendered its findings inconclusive (MacMillan
et al., 2009). . .” [52], p. 6.
Notable in the second extraction is the statement that
the control group was exposed to the intervention even
though no control women were screened. These authors
referred to the IPV screening trial findings as “inconclu-
sive”, which was not the interpretation provided in the
conclusion of the trial (nor in the accompanying editor-
ial), but rather their own, a framing that occurred expli-
citly in at least one additional source [53], and was
implied in several others.
Methodological and statistical concerns about the trial
methods did not extend to the ‘no harms’ finding, how-
ever, and in a number of sources, authors endorsed this
finding as support for screening. This is exemplified in
the following extract:
“This study demonstrates a high level of endorsement
among women for routine intimate partner violence
screening and that no harm or adverse effects were
linked with the intervention, which is consistent with
recent work done by Houry et al. (83) and MacMillan
et al. (65) Thus, the findings support the view that
intimate partner violence screening intervention does
not contravene the principle of nonmaleficence and,
in the right circumstances, may be aligned with
beneficence.” [54] p. 421.
Sometimes, there were contradictory interpretations of
the utility of the trial findings within the same source:
“One of the few randomized studies available reported
that victims whose positive screen results werecommunicated to their physicians had no better
outcomes than women who were simply given a
referral card (MacMillan et al., 2009). Unfortunately,
the retention rate in this study was too low to support
its general conclusion, no evidence was provided from
either study on whether physicians actually used the
information they got from the screen, and a debatable
statistical method was used to neutralize the
reduction in harms that were found. Interestingly,
more than four times as many abused victims who
were screened discussed violence with their physicians
than abuse victims who were not screened (44%
versus 10%), which demonstrates a remarkable effect
of screening.” [55], p. 390.
Some sources seem to overlook certain aspects of the
trial in favour of others when summarizing evidence, for
example, the practice guidelines released by the Regis-
tered Nurses’ Association of Ontario referred to the IPV
screening trial once in its recommendation supporting
universal screening, as follows, with no mention of the
lack of benefit finding:
“Furthermore, studies have shown that: no harm or
adverse effects were linked with this type of
questioning (Houry et al. 2004; Koziol-McLain et al.,
2010; MacMillan et al., 2009).” [56], p. 3.
Some authors who cited the trial did not cite the
major findings, but instead used the citation for different
purposes. Of the 63 sources with a position on screen-
ing, 29% of those deemed supportive of screening and
46% of those deemed not supportive of screening did
not cite either of the main findings specific to harm or
benefit, and instead cited the trial for other reasons such
as more minor findings (e.g., retention rate) or the use of
particular methods. In other cases, authors provided de-
scriptions of the trial findings that seemed to contradict
the actual results, while still supporting a pro-screening
position:
“In a randomised trial MacMillan and colleagues
recently confirmed that screening for domestic
violence is safe and feasible and leads to significant
improvements in quality of life, although the latter
finding disappeared after adjustment for
confounders.” [57], p. 408.
and,
“Although a recently published randomized trial failed
to demonstrate benefit from intimate partner violence
screening, (25) most major medical societies continue
to recommend routine screening of women for
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effects of screening and the development of effective
interventions. Until that time arrives, however,
clinicians should continue to screen all their adult
female patients for partner violence not only for
compliance with national guidelines, but because its
high prevalence and extensive health effects warrant
routine inquiry.” [58], p. 1165.
A more nuanced approach was exemplified in the fol-
lowing extract, as well as in a small minority of other
sources [59]:
“The MacMillan study (21) was important because it
demonstrated the safety of IPV screening, but it is
important to note that their screening intervention
group did not receive any intervention beyond a
referral, and the control group was also screened and
referred only at the end of the visit as opposed to the
beginning. This likely negated any ability to detect a
difference but does not mean that screening and
referral were ineffective since, unlike our results, IPV-
identified women in both groups exhibited long-term
reductions in IPV recurrence (21).” [60], p. 897.
Some authors interpreted the results in the broader
context of an appropriate and meaningful response from
health care settings and professionals to identify and,
more importantly, respond to women experiencing vio-
lence. These types of uses of the evidence are exempli-
fied by the following:
“Despite the lack of evidence supporting effectiveness
of IPV screening (32, 33 (MacMillan et al., 2009)),
there is compelling logic for screening (34,35), and
routine assessment for victimization is supported by
most major medical societies (36). However, requiring
screening questions does not guarantee that clinicians
consistently or effectively implement them, nor that
they respond appropriately to disclosures of abuse
(26). Our findings may reflect that mandating
screening without providing effective and accessible
means of intervening will have a limited impact on
victims.” [61], p. 320.
And,
“In summary, there continues to be a lack of evidence
that universal screening alone improves health
outcomes for IPV survivors. It is certainly
understandable that clinicians and health care
facilities have implemented universal screening
programs, given the prevalence and potential severity
of IPV. However, the results of the study byMacMillan et al. [6] should dispel any illusions that
universal screening with passive referrals to
community services is an adequate response to
violence in intimate relationships. Specific
interventions to prevent the recurrence of abuse for
women at risk of violence should be implemented and
rigorously tested, preferably in randomized trials,
without further delay.” [25], p. 569.
Discussion
The present study analysed the uptake and representa-
tion of a major new source of evidence in an important,
yet complex and contested, health care area. In general,
we found that even evidence from a large trial consid-
ered to be of “fair” quality (i.e., having no major limita-
tions) by the US Preventive Services Task Force [12] and
published in a journal with wide circulation and an ac-
companying editorial clearly summarizing the findings,
is not interpreted consistently in subsequent literature,
including major clinical and public policy documents. In
fact, the article was subject to a number of sometimes
contradictory interpretations and uses, indicating the po-
tential for evidence to be more malleable than might
otherwise be expected. A number of strategies, both ac-
tive and passive, were brought to bear to downplay the
aspects of the trial findings (i.e., no benefit of screening)
when they were inconsistent with specific positions, i.e.,
support for universal screening. These strategies in-
cluded overstating or extending study limitations, while,
in some cases at the same time, selectively appropriating
and/or ignoring the same study limitations about find-
ings more consistent with the stated position (i.e., no
harms of screening or that the screened group reported
more discussion with a clinician). It was interesting that
those who deemed the findings invalid by virtue of
methodological flaws, and used this argument to refute
the lack of benefit, could at the same time find the trial
to have sufficient validity to support the finding of ‘no
harms’ of screening.
We also examined sources citing the trial that pro-
vided specific clinical guidance regarding identification
and/or referral of abused women in various clinical situ-
ations, or for different groups of women. Several of these
were formal clinical practice guidelines (CPGs) prepared
by established groups [50,56,62,63]; in some cases two
or more documents related to the guideline (i.e., evi-
dence summaries, supplements, etc.) were published,
and while all of these were included in the citation
counts, it should be noted that the treatment of the IPV
screening trial was the same in all documents. Other re-
view articles [64,65] endeavoured to provide clinical
guidance, but were not formal guidelines or recommen-
dations endorsed by specific associations or other
groups. Of note, some CPGs published after the trial did
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to support their positions.
Another finding that stands out is related to defini-
tions and terminology; only 12% of the sources we
analysed actually defined what they meant by screening.
While the issue of providing a specific definition may
seem pedantic, the implications of failing to clearly dis-
tinguish different ways to identify women exposed to
violence likely underpins much of the confusion and de-
bate in this area [27]. Consider the following notable ex-
ample of how the lack of common definitions influences
interpretation and use of evidence: the IPV screening
trial was criticized because women in the control group
were said by some to have been exposed to the interven-
tion [44,51,52,60]. However, as reported in the trial,
women in the control group were only asked questions
about violence using self-completed research tools ad-
ministered by a research assistant subsequent to their
encounter with the clinician; this information was never
passed on to the clinician. If, as some argue, asking any
questions about violence, whether linked to a clinical en-
counter or not, is “screening”, then presumably simply
answering any questions about health conditions, such
as depression, diabetes, etc., linked or not to an encoun-
ter with a clinician, is considered screening. This way of
thinking disregards the important element of the
patient-clinician encounter in assessment and diagnosis,
which would be expected to follow a positive screening
result for any condition. In fact this issue was tested in
the more recently published IPV screening trial [26], and
no life quality or other differences were found between
the unscreened group that was asked about violence and
given violence resources, and the “true” control group
that was followed but never exposed to violence ques-
tions or materials. At the other extreme are the several
sources that defined screening to include not only hav-
ing a health care provider ask about IPV, but also couple
the screening with specific follow-up services.
Similarly, case-finding – assessment of a patient based
on risks for, and/or clinical signs or symptoms of, expos-
ure – is often called, in this literature, ‘targeted screen-
ing’ or ‘risk-based inquiry’. Since all professional
associations and guidelines appear to agree that asking
about abuse under these conditions is a minimum stand-
ard of care to better assess immediate safety, and also to
help address potential co-morbid conditions, it is un-
clear why the concept of ‘screening’ needs to be invoked
at all. We were struck by how many sources used the
term screening when in fact they were discussing a dif-
ferent type of inquiry. For example, among the seven
sources supporting inquiry in specific populations or set-
tings where clients would likely be at higher risk for IPV,
almost all used the term ‘screening’. Seeking clarity
about these issues would be an important step inensuring that policies and practices are consistent with
principles of good clinical care, as well as being compar-
able across settings, both for clinical auditing purposes,
and when conducting research and evaluation.
These debates about evidence are not simply esoteric.
Recently, a report by the US Institute of Medicine
(IOM) recommended universal screening, while acknow-
ledging that the evidence supporting it remained limited
[44], a finding reinforced in the 2012 evidence synthesis
[22] and new recommendation (see below) on the topic
by the US Preventive Services Task Force (USPSTF)
[66]. The 2011 IOM Report was used as the basis for in-
cluding IPV screening in the US Affordable Care Act
[67], thereby embedding it in legislation.
However, it is interesting to note how the above promin-
ent guideline documents situate the evidence, and specific-
ally the IPV screening trial, with respect to the actual
recommendations. Both the USPSTF and IOM guidelines
are based on 1) the fact that screening instruments can
identify abuse; 2) there is emerging evidence that specific
interventions might work in some groups of women; and
3) that the IPV screening trial had methodological limita-
tions. The IOM report stresses the issue of “exposure in the
control group”, as described above. As they state, “women
randomized to the unscreened comparison group were also
asked questions about abuse, received information about
intimate partner violence, and were offered services if nee-
ded, reducing measureable differences between screened
and unscreened women” [44], p. 106. The USPSTF evi-
dence review [22], raised similar issues, while providing a
“fair” quality rating, which, applying their evidence rules,
would normally indicate a recommendation in the opposite
direction: fair evidence of no benefit would lead to a D re-
commendation, or, if concerns of generalizability were an
issue (such as the fact that the IPV screening trial was done
in Canada), perhaps an I statement of insufficient evidence
[68]. However, the USPSTF recommendation is a B grade,
stating that “clinicians screen women of childbearing age
for intimate partner violence (IPV), such as domestic vio-
lence, and provide or refer women who screen positive to
intervention services” [66]. While the IOM report, and the
related ACA legislation, preceded the more recently pub-
lished RCT of IPV screening in USA health settings that
also found no benefit of screening [26], the USPSTF guide-
line was published approximately 5 months after publica-
tion of this new trial [66].
From a strictly ‘evidence-based medicine’ perspective,
these decisions may be seen as unusual, or at best a modi-
fication of the usual ‘rules of evidence’ [68] to allow cer-
tain forms of evidence to be more influential than they
normally would. However, from the perspective of the
policy studies literature specific to research utilization,
and an emerging and more nuanced examination of
‘knowledge translation’ and ‘implementation science’
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confusing (though no more ‘evidence-based’). Building on
Weiss’ notion of tactical use of research [69], Greenhalgh
and Wieringa [23], p. 507 eloquently state: “. . .research
evidence may be used instrumentally and rhetorically to
back-up particular value-based positions. This occurs par-
ticularly when there is ‘high issue polarisation’ – that is,
disagreement among stakeholders about what the signifi-
cant problems are and how they might be addressed.” The
notion of ‘evidence-in-context’ is emerging, regardless of
topic area, as the only way to truly understand the ‘trans-
lation’ of ‘knowledge’ to policy and practice; trying to as-
sess the impact of ‘evidence’ without a concurrent
evaluation of the context(s) in which it is to be used in-
creases the likelihood of lack of success of knowledge
translation strategies [34,70,71].
In the context of our case example, decision-makers, re-
searchers, and clinicians are actively engaged in determin-
ing how best to identify and help abused women when
they present to health care settings. The notion of screen-
ing was introduced in the early 1990s to address what the
AMA at that time termed “a major public health problem”
[1], and screening was seen as a way to sensitize clinicians
to the issue, have them identify women, and start a pro-
cess of care and referral. However, as indicated above, the
concept of screening is understood in different ways, and
the reality of adding this clinical activity to the broad
range of actions that primary care clinicians (whether in
the emergency department or a family practice) are al-
ready required to do, with little guidance on what happens
after identification (and little formal training in the issue),
is where the “issue polarisation” described by Greenhalgh
and Wieringa [23] can be seen to emerge.
At the same time, processes and technologies to routinize
certain aspects of assessment and care became prominent,
with a leading trend now being to have women complete
questions about violence exposure (and other ‘lifestyle is-
sues’) on computer kiosks in waiting areas [72,73]. Position-
ing the difficult task of responding to questions about
abuse to a computer, in a room surrounded by other pa-
tients, seems counter to all principles of good care for
women experiencing violence [74]. Given the resource im-
plications for USA health care settings as they work to
comply with ACA legislation and screen all women, it is
conceivable that much of this screening will move to these
computer-assisted models, with women who screen posi-
tive receiving print-outs of local resources. What happens
to women after screening is not spelled out in the guide-
lines reviewed above. Additional evaluation of the imple-
mentation of this legislation in the USA is warranted.
Limitations and future research
It is well acknowledged in the KT literature that one of
the most difficult things to assess is the actual impact ofnew knowledge on specific policies or practices, or, ul-
timately, on health-related outcomes [34,75]. We have
used a highly focused approach to assess the uptake and
representation of a specific new research report in a
range of documents, from news reports to national
guidelines embedded in legislation. Our modified cit-
ation analysis was able to capture formal and informal
published material in the time-span for the review; how-
ever, it would have missed documents, especially in the
grey literature, unable to be located with our search pro-
cesses. The analysis, and our interpretation, were limited
in their ability to understand the ‘why’ and ‘how’ of the
decisions that went into the use (or non-use) of the trial
report – published reports rarely explicitly describe the
decisions that underpin selection and use of evidence,
whether by a sole author, or a consensus committee.
Methods that can triangulate analysis of both the end
products of knowledge use, as well as the decision pro-
cesses, for example through qualitative and/or observa-
tional research with decision-makers as they interact
with the new evidence and decide whether/how to use
it, would enrich this kind of analysis.
It should also be noted that, in addition to the JAMA
publication, the findings of the trial, and a series of related
studies, were disseminated more broadly using a number
of tailored and more general KT strategies. These are
described in depth in other publications [76,77], and
included knowledge-sharing events tailored to specific au-
diences (i.e., policy briefings to Canadian government rep-
resentatives, a clinical live chat via the JAMA Author-in
-the-Room platform for a related study), general dissemi-
nation including press releases and media interviews, and
a series of knowledge exchange forums with mixed groups
of stakeholders in Canada (researchers, policy-makers, ad-
vocates, and clinical leaders in the area of family violence).
The extent to which these other, generally more local, ac-
tivities influenced use of the trial report in the documents
described in this study are unknown, however they are
likely minimal given the international scope of the litera-
ture included in this analysis.
It is important to highlight that two of the study au-
thors were co-authors of the IPV screening trial, which
formed the impetus for this analysis. To reduce potential
bias in the data collection and analysis processes, these
aspects of the study were conducted by two investigators
not associated with the original IPV screening trial, who
independently coded all extractions using established
protocols for this type of content analysis, and who ini-
tially determined how these data were grouped into
themes, including pre-selection of potential quotes that
could be used in the qualitative analysis to emphasise
(or provide contrary viewpoints) on these themes.
Finally, since articles on the topic not citing the trial
would, according to the inclusion criteria, not be included,
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findings from the IPV trial. In other words, there are rele-
vant articles that might well have cited this study in some
capacity but chose not to. A search conducted to identify
potentially high-impact documents such as guidelines and
policy or position papers did yield some examples of this,
including the practice guideline of the American Congress
of Obstetricians and Gynecologists [17], and a “guidance
memo” to all health professionals from the Director of the
US Department of Health and Human Services’ National
Health Resource Center on Domestic Violence and the
Senior Public Policy Advocate of the advocacy group Fu-
tures Without Violence [18]. Both of these documents
recommended screening, reinforcing the finding that some
authors and organizations chose not to include the trial
when formulating positions not consistent with its findings.
While the areas of health policy and clinical practice dif-
fer somewhat in terms of how they use evidence, as well as
what kinds of evidence matter, much of the discourse in
both areas assumes that these processes should include
consideration of research and laments the lack of its
uptake, especially when there are proven-effective interven-
tions [78-80]. This paper highlights a different pheno-
menon – the push to develop public and clinical policy
when the available evidence does not, on its face, support
specific actions. While it is true that current thinking in
the area of evidence-informed policy and practice pro-
motes the use of higher levels of evidence (i.e., systematic
reviews of multiple trials, rather than individual studies) to
support decisions [81], it does become a challenge to the
‘chain of evidence’ when these trials are mis- or un-
represented in the evidence syntheses. More studies analys-
ing this aspect of research mis- and non-utilization would
assist in understanding whether our findings were specific
to the context of IPV screening, or are seen more broadly.
Similarly, while there is an emerging literature on the role
of so-called ‘negative trials’ in health care – those that
show no difference or negative outcomes related to the
intervention [82] – and guidance is available regarding
making policy decisions in the face of uncertain evidence
[83], it is clear that it is difficult to engage decision-makers
in using evidence [84]. Even when compelling evidence
emerges demonstrating that an existing practice is ques-
tionable or even detrimental, established practices and pol-
icies may not change [82]. Indeed, many of the same
features of evidence-informed decision-making processes
highlighted in our analysis have been described in other
policy-oriented KT studies [85]. The type of analysis
conducted in this study might serve as a useful form of
“reality-check” when assessing a new practice or policy –
has the policy included consideration of all potentially rele-
vant evidence, as well as the myriad other factors (includ-
ing tacit knowledge, resource implications, contextual
factors, etc.) that surround any such decision? The role ofnegative trials, and contrary evidence in general, in public
and community health practice and policy, requires further
research.
Conclusions
Our findings highlight the importance of considering the
malleability of research evidence and its potential for
both intended, and unintended, uses. They provide em-
pirical data regarding what many have written about re-
garding barriers to evidence-based decision-making and
research utilization [23,34,69-71], they have implications
for understanding how research evidence is taken-up
and interpreted in policy and practice, and they can in-
form development of specific KT strategies in contested
knowledge areas. Our analysis provides a good example
of what Greenhalgh and Wieringa [23], p. 501, describe
as “knowledge [that] obstinately refuses to be driven un-
problematically into practice.”
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